argenx SE (ARGX) Revenue & Revenue Breakdown
argenx SE Revenue Highlights
Latest Revenue (Y)
$1.23B
Latest Revenue (Q)
$401.00M
Main Geography (Y)
United States
argenx SE Revenue by Period
argenx SE Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $1.23B | 198.56% |
2022-12-31 | $410.75M | -17.40% |
2021-12-31 | $497.28M | 1009.97% |
2020-12-31 | $44.80M | -42.69% |
2019-12-31 | $78.17M | 218.10% |
2018-12-31 | $24.57M | -43.75% |
2017-12-31 | $43.69M | 182.33% |
2016-12-31 | $15.47M | 106.49% |
2015-12-31 | $7.49M | 64.07% |
2014-12-31 | $4.57M | 23.56% |
2013-12-31 | $3.70M | 69.30% |
2012-12-31 | $2.18M | 49.75% |
2011-12-31 | $1.46M | - |
argenx SE Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-03-31 | $401.00M | -1.58% |
2023-12-31 | $407.43M | 23.54% |
2023-09-30 | $329.79M | 21.90% |
2023-06-30 | $270.55M | 23.46% |
2023-03-31 | $219.14M | 25.83% |
2022-12-31 | $174.16M | 26.22% |
2022-09-30 | $137.98M | 83.50% |
2022-06-30 | $75.19M | 221.18% |
2022-03-31 | $23.41M | -10.03% |
2021-12-31 | $26.02M | 2936.41% |
2021-09-30 | $857.00K | -99.73% |
2021-06-30 | $312.24M | 97.43% |
2021-03-31 | $158.16M | -4354.65% |
2020-12-31 | $-3.72M | -132.41% |
2020-09-30 | $11.47M | -34.53% |
2019-12-31 | $17.52M | 100.63% |
2019-09-30 | $8.73M | 2.02% |
2019-06-30 | $8.56M | -79.09% |
2019-03-31 | $40.94M | 2779.29% |
2018-12-31 | $1.42M | -41.83% |
2018-09-30 | $2.44M | -82.34% |
2018-06-30 | $13.84M | 101.54% |
2018-03-31 | $6.87M | -33.43% |
2017-12-31 | $10.32M | 34.09% |
2017-09-30 | $7.69M | -58.56% |
2017-06-30 | $18.56M | 160.87% |
2017-03-31 | $7.12M | 93.52% |
2016-12-31 | $3.68M | -33.21% |
2016-09-30 | $5.51M | 45.64% |
2016-06-30 | $3.78M | 50.51% |
2016-03-31 | $2.51M | 32.96% |
2015-12-31 | $1.89M | -26.43% |
2015-09-30 | $2.57M | 48.66% |
2015-06-30 | $1.73M | 31.80% |
2015-03-31 | $1.31M | -26.42% |
2014-12-31 | $1.78M | -11.35% |
2014-09-30 | $2.01M | 550.83% |
2014-06-30 | $308.66K | -34.19% |
2014-03-31 | $468.99K | -49.81% |
2013-12-31 | $934.37K | -44.12% |
2013-09-30 | $1.67M | 215.10% |
2013-06-30 | $530.61K | -5.18% |
2013-03-31 | $559.63K | - |
argenx SE Revenue Breakdown
argenx SE Revenue Breakdown by Country
Annual Revenue by Country
Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
---|---|---|---|---|---|
China | $14.91M | - | - | - | - |
United States | $1.05B | $377.66M | - | - | - |
Japan | $56.43M | $15.76M | - | - | - |
EMEA | $72.85M | - | - | - | - |
Europe | - | $5.68M | - | - | - |
DENMARK | - | - | $1.39M | - | - |
Others | - | - | $123.00K | - | - |
UNITED STATES | - | - | $317.40M | - | - |
CHINA | - | - | $178.37M | - | - |
U | - | - | - | $36.13M | - |
D | - | - | - | $299.00K | $436.00K |
L | - | - | - | - | $27.26M |
C | - | - | - | - | $40.59M |
Latest
Quarterly Revenue by Country
Country | Dec 23 | Jun 23 | Jun 22 | Jun 21 | Jun 20 | Jun 19 |
---|---|---|---|---|---|---|
United States | $605.74M | $440.85M | $94.35M | - | - | - |
EMEA | $50.02M | $22.84M | - | - | - | - |
Japan | $32.79M | $23.64M | $1.51M | - | - | - |
Other | - | - | $133.00K | - | - | - |
Countries Other Than United States And China | - | - | - | $1.24M | - | - |
U | - | - | - | $317.26M | $22.27M | - |
C | - | - | - | $151.90M | $15.31M | - |
D | - | - | - | - | $120.00K | $128.00K |
L | - | - | - | - | - | $26.60M |
Latest
argenx SE Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
BGNE | BeiGene | $2.46B | $929.17M |
ALNY | Alnylam Pharmaceuticals | $1.83B | $420.15M |
ARGX | argenx SE | $1.23B | $401.00M |
AMLX | Amylyx Pharmaceuticals | $380.79M | $416.00K |
APLS | Apellis Pharmaceuticals | $366.28M | $176.57M |
LEGN | Legend Biotech | $285.14M | $93.99M |
ZLAB | Zai Lab | $266.72M | $100.50M |
ASND | Ascendis Pharma | $266.72M | $95.89M |
BPMC | Blueprint Medicines | $249.38M | $128.18M |
TVTX | Travere Therapeutics | $145.24M | $62.90M |
KRTX | Karuna Therapeutics | $654.00K | - |
PCVX | Vaxcyte | - | - |
DAWN | Day One Biopharmaceuticals | - | $20.07M |
TERN | Terns Pharmaceuticals | - | - |
AKRO | Akero Therapeutics | - | - |